Neurocrine Biosciences, Inc.

138.02-9.36 (-6.35%)

Oct 29, 4:00:00 PM EDT · NasdaqGS · NBIX · USD

Upcoming Earnings

Report date

EPS

2.01 (1.77 ~ 2.45)

Revenue

769.94M (722.70M ~ 848.49M)

Key Stats

Market Cap

13.76B

P/E (TTM)

33.02

Basic EPS (TTM)

4.18

Dividend Yield

Recent Filings

10-Q

10/28/25Oct 28, 2025

8-K

10/28/25Oct 28, 2025

10-Q

Q2 FY2025 results

7/30/25Jul 30, 2025

Neurocrine Biosciences posted solid Q2 FY2025 results, with total revenues climbing 16.5% y/y to $687.5M on surging INGREZZA net product sales of $624.4M (up 7.7% y/y) and early CRENESSITY contributions of $53.2M, while collaboration revenues dipped slightly to $5.5M. Operating income held steady at $145.6M y/y despite R&D expenses jumping 27.8% to $244.3M from pipeline investments like Phase 3 starts for NBI-1117568 in schizophrenia and osavampator in MDD; SG&A rose 18.4% to $286.3M on commercial expansion. Diluted EPS improved to $1.06 (up 68.3% y/y), reconciling cleanly to net income of $107.5M over 101.0M shares. Cash from operations for the half-year reached $166.8M, yielding free cash flow of $143.6M after $23.2M capex, bolstering liquidity to $1,849.4M in cash and marketable securities with no debt; share repurchases totaled $167.7M under the $500M program. Patent challenges from generics loom as a key risk.

8-K

Strong Q2 sales growth

7/30/25Jul 30, 2025

Neurocrine Biosciences posted Q2 2025 total revenues of $688 million, up 17% year-over-year, fueled by INGREZZA's $624 million in net sales—8% higher than last year—and CRENESSITY's $53 million debut amid robust demand with 664 new patient enrollments. The company narrowed 2025 INGREZZA guidance to $2.5-$2.55 billion, reflecting volume gains offset by pricing pressures from expanded Medicare access covering 70% of beneficiaries. Yet a Phase 3 schizophrenia study for valbenazine missed its primary endpoint. Pipeline advances include starting Phase 3 for NBI-568 in schizophrenia.

8-K

CMO succession announced

5/30/25May 30, 2025

Neurocrine Biosciences announced on May 30, 2025, that Sanjay Keswani, M.D., will succeed Eiry W. Roberts, M.D., as Chief Medical Officer effective June 2, 2025, with Roberts transitioning to Strategic Advisor to the CEO through December 31, 2025. She retains her $731,400 base salary and 60% target incentive bonus eligibility, while her equity awards continue vesting normally. This smooth handover preserves institutional knowledge amid the leadership shift.

About

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

CEO

Mr. Kyle W. Gano Ph.D.

IPO

5/23/1996

Website

https://www.neurocrine.com

Employees

1,800

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic